Zobrazeno 1 - 10
of 162
pro vyhledávání: '"Susan M Richards"'
Publikováno v:
Frontiers in Cellular and Infection Microbiology, Vol 2 (2012)
Salmonella enterica serovar Typhimurium uses two-component regulatory systems (TCRSs) to respond to environmental stimuli. Upon infection, the TCRSs PhoP-PhoQ (PhoPQ) and PmrA-PmrB (PmrAB) are activated by environmental signals detected in the lumen
Externí odkaz:
https://doaj.org/article/5733916249ca42179a5c1955518950d2
Publikováno v:
PLoS ONE, Vol 7, Iss 11, p e49588 (2012)
Salmonella enterica serovar Typhimurium (S. Typhimurium) uses two-component regulatory systems (TCRS) to respond to stimuli in the local microenvironment. Upon infection, the Salmonella TCRSs PhoP-PhoQ (PhoPQ) and PmrA-PmrB (PmrAB) are activated by e
Externí odkaz:
https://doaj.org/article/d930fecf54784da38b8f84fb02f22c15
Publikováno v:
Frontiers in Immunology, Vol 11 (2020)
Externí odkaz:
https://doaj.org/article/eae2a3670ea84f6b944468b1496bba5f
Autor:
Johanna R. Mora, Susan M. Richards
Publikováno v:
The AAPS Journal. 25
Autor:
Anne S. De Groot, Sophie Tourdot, Gregor P Lotz, Nikki Dellas, Arno Kromminga, Luca Piccoli, Carolina B Quaglia, Susan M. Richards, Günter Waxenecker, Eric Guillemare, Federico Mingozzi, Samuel O. Pine, Paul Chamberlain, Daniel Kramer
Publikováno v:
Bioanalysis. 12:1043-1048
Given the expanding number of complex therapeutic protein drugs and advanced therapy medicinal products that are being developed, improving our ability to assess the potential immunogenicity of biologics is critical to ensuring treatment efficacy and
Autor:
Martin S. Tallman, Susan M. Richards, Xin V. Wang, David I. Marks, Anthony H. Goldstone, Charles G. Mullighan, Jacob M. Rowe, Mark R. Litzow, Georgina Buck, Peter H. Wiernik, Kathryn G. Roberts, Letizia Foroni, Cheryl L. Willman, Dan Douer, Chezi Ganzel, Hillard M. Lazarus, Elisabeth Paietta, Selina M. Luger
Publikováno v:
British Journal of Haematology
Summary Late relapse [>3 years from complete remission (CR)] in acute lymphoblastic leukaemia (ALL), is unusual. Data from the MRC UKALLXII/ECOG E2993 trial are presented to evaluate the incidence and characteristics of late relapse in adult ALL. Of
Autor:
Jim McNally, Szilárd Kamondi, Daniel Kramer, Honglue Shen, Vibha Jawa, Jane Ruppel, Charles S Hottenstein, Kelli R. Phillips, Meina Liang, Michael E Hodsdon, Dong Geng, Joanne Goodman, Mohsen Rajabi Ahbari, Heather Myler, Marta Starcevic Manning, Alvydas Mikulskis, William Hallett, Haoheng Yan, Adrienne Clements-Egan, Paul Chamberlain, Qiang Qu, ZhenZhen Liu, Carol Gleason, Viswanath Devanaryan, George R Gunn, Susan M. Richards, Theresa J Goletz, Troy E. Barger, Susana Liu, Lakshmi Amaravadi, Veerle Snoeck, Joao Pedras-Vasconcelos, Kathryn Lindley, Robert Nelson, Mark Ware, Shobha Purushothama, An Song, Susan Kirshner, Brian M Janelsins, Jad Zoghbi, Steven Bowen, Ronald R. Bowsher
Publikováno v:
The AAPS Journal. 24
Evolving immunogenicity assay performance expectations and a lack of harmonized anti-drug antibody validation testing and reporting tools have resulted in significant time spent by health authorities and sponsors on resolving filing queries. Followin
Publikováno v:
Frontiers in Immunology, Vol 11 (2020)
Autor:
Susan M. Richards, Alexandra Joseph, Richard Brennan, Jose Luis Vela, Tran Johnson, Mindy Zhang, Errin Roberts, Faizan Zubair, Petra Oliva, Peter A. Piepenhagen, Martha Stapels, Dinesh S. Bangari, Deepak Grover
Publikováno v:
Clin Exp Immunol
Summary Biological treatments such as enzyme-replacement therapies (ERT) can generate anti-drug antibodies (ADA), which may reduce drug efficacy and impact patient safety and consequently led to research to mitigate ADA responses. Transient low-dose
Autor:
Jeffrey S. Heier, Abraham Scaria, Samuel C. Wadsworth, Shilpa J. Desai, Susan M. Richards, Peter A. Campochiaro, Annie Purvis, Seng H. Cheng, Saleema Kherani, Rafael Varona, John Connelly, Annaig Le-Halpere, Cheryl Delacono, Shalesh Kaushal, Pravin U. Dugel, Ronald Buggage
Publikováno v:
The Lancet. 390:50-61
Summary Background Long-term intraocular injections of vascular endothelial growth factor (VEGF)-neutralising proteins can preserve central vision in many patients with neovascular age-related macular degeneration. We tested the safety and tolerabili